Incyte (INCY) Interest Coverage Ratio Growth (3y) (2013 - 2026)
Incyte (INCY) Interest Coverage Ratio Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,831.58 Bn | 66,831.30 Bn | - | -42.41% |
| 2 | Nanobiotix | 1,916.61 Bn | 1,916.55 Bn | - | - |
| 3 | Akari Therapeutics | 976.78 Bn | 976.78 Bn | - | - |
| 4 | BeOne Medicines | 471.48 Bn | 466.69 Bn | 1.35 Bn | 28.11% |
| 5 | Vertex Pharmaceuticals | 121.78 Bn | 114.53 Bn | 2.59 Bn | -6.89% |
| 6 | Regeneron Pharmaceuticals | 69.87 Bn | 61.12 Bn | 3.31 Bn | 79.27% |
| 7 | Belite Bio | 63.06 Bn | 63.06 Bn | - | - |
| 8 | Argenx Se | 55.78 Bn | 50.60 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.54 Bn | 34.53 Bn | 959.66 Mn | 40.09% |
| 10 | Incyte | 23.75 Bn | 19.73 Bn | 1.17 Bn | 119.92% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 119.92% |
| Dec 31, 2025 | 365.82% |
| Sep 30, 2025 | 41.25% |
| Jun 30, 2025 | 19.78% |
| Mar 31, 2025 | 14.15% |
| Dec 31, 2024 | -40.70% |
| Sep 30, 2024 | 97.56% |
| Jun 30, 2024 | -253.52% |
| Mar 31, 2024 | 123.26% |
| Dec 31, 2023 | -69.47% |
| Sep 30, 2023 | 312.41% |
| Jun 30, 2023 | 7.39% |
| Mar 31, 2023 | 26.45% |
| Dec 31, 2022 | 60.45% |
| Sep 30, 2022 | 20.21% |
| Jun 30, 2022 | 43.65% |
| Mar 31, 2022 | -2.35% |
| Dec 31, 2021 | 53.13% |
| Sep 30, 2021 | 147.33% |
| Jun 30, 2021 | -17.38% |